机构

• 上海药物研究所 [8]

采集方式

• OAI收割 [8]

内容类型

• 期刊论文 [8]

发表日期

• 2021 [4]
• 2020 [3]
• 2019 [1]

学科主题

筛选

浏览/检索结果: 共8条，第1-8条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei   |  收藏  |  浏览/下载：76/0  |  提交时间：2022/01/04 furmonertinib  autoinduction  food effect  alkaline phosphatase  body weight  pharmacokinetics  modeling and simulation  NSCLC   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun   |  收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun   |  收藏  |  浏览/下载：61/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文  OAI收割 INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8 作者:     |  收藏  |  浏览/下载：37/0  |  提交时间：2021/05/24 Alflutinib  Rifampicin  CYP3A4  AST5902  Drug-drug interaction   Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins 期刊论文  OAI收割 DRUG METABOLISM AND PHARMACOKINETICS, 2020, 卷号: 35, 期号: 5, 页码: 456-465 作者:  Liu, Xiaoyun;  Feng, Dan;  Zheng, Mingyue;  Cui, Yongmei;  Zhong, Dafang   |  收藏  |  浏览/下载：30/0  |  提交时间：2020/12/21 Covalent tyrosine kinase inhibitors  Covalent binding  Human serum albumin  Molecular docking  Quantitative calculations  Linear modeling  Species difference   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文  OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong   |  收藏  |  浏览/下载：82/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11 作者:  Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan   |  收藏  |  浏览/下载：97/0  |  提交时间：2020/07/01 alflutinib  AST5902  metabolism  enzyme induction  drug-drug interaction   Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文  OAI收割 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6 作者:  Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu   |  收藏  |  浏览/下载：43/0  |  提交时间：2020/07/01 LC-MS/MS  Alflutinib  AST2818  Pharmacokinetics  Human plasma